Hi [[ session.user.profile.firstName ]]

MPI Research

  • Date
  • Rating
  • Views
  • Common Challenges to Overcome While Conducting BSL2 Studies Common Challenges to Overcome While Conducting BSL2 Studies Stephene Rose, MBM, James Justen, BS, Keith Nelson, PhD, DVM, DACVP,Joseph Hampel, DVM, DACLAM Recorded: Dec 8 2016 58 mins
    Preclinical laboratories face several challenges when conducting animal studies requiring Biosafety Level (BSL) 2 level containment. Some of these challenges include informed study design (including knowledge of associated regulatory guidelines), proper preparation of the vivarium, species isolation, traffic control between containment areas, training of personnel, veterinarian care, and proper decontamination of equipment/waste/bedding prior to disposal. In addition, proper post-life handling of animals and samples, with focused attention on tissue sampling and specialized evaluation is a vital element in ensuring personnel safety and high scientific quality. Overcoming these hurdles will generate high quality data and allow for a safe and productive environment.
  • How Do I Get My Compound Into Phase I? How Do I Get My Compound Into Phase I? Scott Boley, PhD, DABT, Greg Ruppert, BA Recorded: Nov 3 2016 58 mins
    Careful assessment of the relationship between efficacy and toxicity is vital to drug developers as they seek advancement of their compounds. Nonclinical testing is required to establish a safe starting dose for the initial human clinical trials. In partnering with our pharmaceutical and biotechnology Sponsors, our goal is to improve the odds of selecting the right lead candidates, and to conduct the right studies in the right way, taking all factors into consideration to ensure a successful IND submission.
    As part of this webinar we will outline the nonclinical studies needed to progress a therapeutic into a Phase I clinical trial. We will cover small molecules to vaccines to biopharmaceuticals as well as standard indications to life-threatening and rare/orphan indications.
  • Common Technical Challenges with Outsourcing Nonclinical Studies Common Technical Challenges with Outsourcing Nonclinical Studies Scott Boley, PhD, DABT, Greg Ruppert, BA Recorded: Sep 29 2016 61 mins
    A primary challenge for pharmaceutical and biotechnology companies in developing their drugs is to carefully assess the relationship between efficacy and toxicity before entering into human clinical trials. Nonclinical testing is required to evaluate the potential efficacy of a new therapeutic and establish a safe starting dose for initial human clinical trials. Knowing when and where to invest your time and effort in preparing for these nonclinical studies is a critical component of a company’s drug development strategy. Many companies outsource their nonclinical testing to contract research organizations (CROs) and have little to no prior experience in working with a CRO. There are a number of technical challenges involved in the process of outsourcing, which if not taken under consideration, can cause delays and unexpected expenses in developing a compound. These challenges range from determining which species is appropriate for your project to basic formulation and dosing aspects. Being aware of and mitigating as many of these challenges early in the process as possible reduces the potential for delays and allows a company to proceed with increased confidence. This webinar will describe some common technical challenges that we have encountered while working with our Sponsors.
  • The CRO+Consultant+Sponsor Relationship The CRO+Consultant+Sponsor Relationship Grace M. Furman, PhD, DABT; President & CEO, Paracelsus, Inc. Ronald Christopher, PhD, DABT, VP, Arena Pharmaceuticals, Inc. Recorded: May 20 2016 60 mins
    The CRO+Consultant+Sponsor Relationship: Collaborating to Ensure Sponsor and Client Success.Collaboration is the key to a successful consulting partnership. This webinar will focus on the responsibilities and perspectives of key stakeholders (Sponsor, consultant and CRO), how to make the most out of the Sponsor/consultant relationship, and key considerations when partnering with a contract research organization. Explore ways to optimize your consultant relationships to ensure success!
  • Need It, Want It, Gotta Do It: How to Optimize Your Nonclinical ADME Studies Need It, Want It, Gotta Do It: How to Optimize Your Nonclinical ADME Studies Richard Slauter, PhD, Andrew Augustine, MS, Rachel Goldsmith, PhD Recorded: Oct 7 2015 56 mins
    We all need to do Absorption, Distribution, Metabolism, and Excretion (ADME) studies to support an NDA submission, but when does ADME data best support the story we are crafting for the agency? When can it benefit us most scientifically? When can it help us move our program successfully forward?

    ADME studies are a vital part of the comprehensive safety evaluation of a new therapeutic entity, whether biologic or small molecule in nature. In vitro ADME evaluations typically inform the nonclinical species selection and give insight into the potential clearance and metabolic profile. All of these data must be confirmed in vivo.

    In vivo ADME studies in laboratory animals (rodents, dogs, nonhuman primates, etc.), typically using some form of the radio-labeled therapeutic entity, are required before NDA submission. These in-life studies provide information regarding pharmacokinetics, biodistribution, rates and routes of elimination, metabolites, relative bioavailability, formulation, dosing frequency, exposure, etc. This is all information that can be leveraged at different points in the drug development process to select a lead compound, add value to that compound, enhance the quality of safety studies, or inform decisions about clinical design. The earlier in the drug development pathway that in vivo ADME data are available, the sooner this information can be leveraged in the design of the nonclinical and clinical development plans.

    This presentation will focus on the questions around when to conduct the nonclinical ADME studies (pre-IND, Phase I, Phase II, Phase III, pre-NDA) to give the greatest benefit to your program, and how to optimize the design to be most expeditious and cost effective while still delivering the necessary data.
  • Hitting the Target: Advancing Therapeutics Through Targeted Delivery Hitting the Target: Advancing Therapeutics Through Targeted Delivery Jeffrey Allen, PhD – Senior Study Director Recorded: Sep 24 2015 44 mins
    The advent of advanced therapeutics such as proteins, viral vectors, stem cells, oligonucleotides and compounds encapsulated in liposomes or nanoparticles have allowed potential therapies for a number of previously undertreated or untreatable central nervous system (CNS) diseases. These include neurodegenerative diseases (Parkinson’s, ALS, Alzheimer’s, Huntington's and spinal muscular atrophy), disorders of lipid metabolism or storage (lysosomal storage diseases), CNS cancers (glioblastomas and meningiomas) and pain. A common issue encountered by all the therapeutic modalities for these disease states is how do you deliver treatments where they are needed at therapeutic levels without producing adverse systemic effects? The increasingly common answer to these issues is the use of targeted delivery. This may include acute, intermittent or continuous delivery to the cerebral spinal fluid (CSF) either by intracerebroventricular or intrathecal administration, direct intraparenchymal or intratumoral delivery with or without convection enhanced delivery (CED) and epidural or perineural dosing. This webinar will focus on the unique aspects related to performing preclinical toxicology studies for targeted therapies within the CNS. These include issues of choosing the correct species, route of administration, performing pharmacokinetics and biodistribution analysis and histopathology.
    Understanding the key considerations driving appropriate study designs to provide data, which are impactful on study specific objectives, as well as, inform high-level program decisions is critical for the execution of successful imaging trials. Likewise, robust, scientifically sound data analysis and accurate interpretation of results is equally as important when applying imaging as a solution within development efforts.
  • See The Forest Through The Trees See The Forest Through The Trees Scott Haller, MS, Jacob Hesterman, PhD, Ken Zasadny, PhD, Howard Dobson, Vice President, Kelly Orcutt, PhD Recorded: Jun 25 2015 58 mins
    Contemporary drug development is well understood to be a lengthy process. Translational research approaches, focused herein on those involving molecular imaging (MI), have improved to decrease time through both micro- and macro-level assessments through the provision of robust data sets. As a multidisciplinary field, the focus of MI is the evaluation of biological processes at the molecular, cellular, whole organ, and/or system level in vivo. Improvements in imaging instrumentation and informatics over the past decade have enabled an increase in novel, translational in vivo imaging applications with comparable (relative) resolution and sensitivity between preclinical and clinical imaging.

    Understanding the key considerations driving appropriate study designs to provide data, which are impactful on study specific objectives, as well as, inform high-level program decisions is critical for the execution of successful imaging trials. Likewise, robust, scientifically sound data analysis and accurate interpretation of results is equally as important when applying imaging as a solution within development efforts.

    This webinar will focus on how translational molecular imaging is employed in drug development through presentation of fundamental key considerations in study design as driven by analysis defined requirements which ultimately facilitates sound data interpretation. The research approaches presented will demonstrate how imaging can be successfully applied in development efforts providing data upon which informed decisions can be based in preclinical and clinical efforts. All participants will have the opportunity to ask questions and discuss relevant issues.
  • Significance of Otic Microscopy in Auditory Safety Studies Significance of Otic Microscopy in Auditory Safety Studies Phaedra Cole, DVM, DACVP, Principal Pathologist Recorded: Dec 4 2014 55 mins
    The United States Food and Drug Administration (FDA) require that otic microscopy be performed on all drug formulations that penetrate the tympanum, or are suspected to come into contact with the middle or inner ear. The auditory system contains critical structures within the middle and inner ear which act to amply and conduct sound before neural processing. Drug-related tissue reactions can result in conductive hearing loss, making otic microscopy a decisive endpoint when determining drug effects on hearing. This webinar will address which otic structures should be evaluated on auditory safety studies to assess impact on audition. Approaches to tissue processing, orientation, and microtomy will be discussed, as the middle and inner ear are embedded in bone and yielding satisfactory slides for histopathologic evaluation can be challenging. Furthermore, this webinar will provide an overview of background pathological findings and drug-related tissue reactions observed in laboratory animals.
  • Evaluating Drug Efficacy in Animal Models of Otic Disorders Evaluating Drug Efficacy in Animal Models of Otic Disorders Matthew Abernathy, PhD, LATG, Associate Research Scientist I, Joshua Yoder, BS, LATG, CMAR, Associate Research Scientists Recorded: Nov 12 2014 57 mins
    The auditory system is responsible for complex processing of environmental stimuli to ultimately enable appropriate integrative responses. This system is regularly exposed to noxious noise intensities as well as drugs and chemicals, potentially precipitating system compromise. Accordingly, the development of new therapeutics to address various aspects of auditory system dysfunction represents an area of intense industry focus. To evaluate the efficacy of a drug regarding preventative or restorative effects on audition, sensitive animal models must be developed to reliably detect changes in relevant endpoints. This presentation will review animal models of otic disorders used to characterize drug candidate efficacy. Specifically, animal models of aminoglycoside ototoxicity, cisplatin ototoxicity, aspirin-induced tinnitus, noise-induced hearing loss, and age-related hearing loss will be discussed in depth. Additionally, available in vivo and histologic immunofluorescent techniques will be reviewed according to opportunities for the incorporation into these models.
  • Preclinical Testing for Safety of Food Ingredients in Infant Formula Preclinical Testing for Safety of Food Ingredients in Infant Formula Bjorn Thorsrud, PhD, MPI Research, Director Brinda Mahadevan, PhD Abbott Nutrition, Manager Recorded: Oct 16 2014 65 mins
    Practical Considerations of Preclinical Testing for Safety of Food Ingredients in Infant Formula

    This webinar will focus on reviewing available research models, including practical considerations for preclinical study designs, as well as providing an overview of the regulatory requirements for evaluating the safety of ingredients in infant formula.